Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients

NCT02496039 is registered in ClinicalTrials.gov with Avanir Pharmaceuticals as lead sponsor.

NCT NCT02496039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02496039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients
Lead sponsor
Avanir Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2015
Completion date
May 31, 2016
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pseudobulbar affect (involuntary laughing and/or crying)